Northwest Biotherapeutics   Report issue

For profit Phase 2 Phase 3
Founded: Bethesda MD United States (1998)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2002
NCT00043212
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Northwest Biotherapeutics

Active Ingredients

Drugs in Phase 3 Trials (1)

tumor-pulsed dendritic cells (3 trials)

Drugs in Phase 2 Trials (3)

dcvax-direct (2 trials)

dcvax-l (3 trials)

nivolumab (opdivo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Astrocytoma (Phase 3)

Brain Neoplasms (Phase 3)

Glioblastoma (Phase 3)

Glioma (Phase 3)

Gliosarcoma (Phase 2)

Lung Neoplasms (Phase 1)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 2)

Neoplasms, Second Primary (Phase 1)

Oligodendroglioma (Phase 2)

Ovarian Neoplasms (Phase 2)

Peritoneal Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 4